Abstract| Volume 51, SUPPLEMENT 1, S4, March 2015

Download started.


ITOC2 – 011. Identification of second-generation potent and selective inhibitors of indoleamine-2,3-dioxygenase-1 (IDO1) for the treatment of cancer

      This paper is only available as a PDF. To read, Please Download here.


      IDO1 inhibition with a 1st-generation inhibitor has shown promising clinical benefit in melanoma patients, as well as exacerbated toxicity, when combined with ipilimumab. We have identified a novel class of IDO1 inhibitors (IDO1i), which surpass the potency, selectivity and pharmacokinetic parameters of 1st-generation IDO1i.


      IDO1 inhibition was assessed from kynurenine (kyn) levels produced by stimulated HeLa or dendritic cell cultures or recombinant IDO1. T-cell proliferation was measured using eFluor®670 dye. CT26 tumours were grown SC in Balb/c mice. IDO1i and kyn levels were measured by LC/MS/MS. Assessment of immune parameters was performed on tumour-infiltrating leucocytes by FACS.


      These IDO1i potently inhibit cellular IDO1 with IC50 ≤ 10 nM, retain their potency in human serum (IC50 ≤ 10 nM) and restore T-cell proliferation, which is inhibited by allogeneic IDO1 + DC (EC50 = 2–5 nM). They exhibit PK characteristics consistent with once-daily dosing in humans. One of these molecules, selected for clinical evaluation, has undergone extensive characterisation, including the relationship between plasma levels of compound and kyn, and its impact on tumour growth and immune parameters in mouse syngeneic tumours, as single agent and in combination with various immune checkpoint inhibitors.


      This study provides the preclinical basis for clinical evaluation of a 2nd-generation IDO1i in combination with other immunotherapies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect